Article Data

  • Views 539
  • Dowloads 140

Original Research

Open Access

The role of Asprosin in the diagnosis of diabetic and non-diabetic patients with sepsis

  • Semra Aytürk Salt1,*,
  • Nurettin Aydoğdu2
  • Ömer Salt3
  • Nihayet Fırat4
  • Necdet Süt5

1Department of Endocrinology and Metabolic Diseases, Kayseri City Hospital, 38080 Kayseri, Turkey

2Department of Medical Physiology, İnönü University, 44000 Malatya, Turkey

3Department of Emergency Medicine, Kayseri City Hospital, 38080 Kayseri, Turkey

4Department of Medical Physiology, Trakya University Medical Faculty, 22100 Edirne, Turkey

5Department of Biostatistics and Medical Information, Trakya University Medical Faculty, 22100 Edirne, Turkey

DOI: 10.22514/sv.2024.056 Vol.20,Issue 5,May 2024 pp.40-45

Submitted: 26 October 2023 Accepted: 22 December 2023

Published: 08 May 2024

*Corresponding Author(s): Semra Aytürk Salt E-mail:


Sepsis is among the major causes of mortality in the world due to its delayed diagnosis and inadequate treatment. Due to the high morbidity and mortality rates, a widely accepted biomarker is required for its diagnosis. Present study aimed to evaluate the serum asprosin levels in septic patients and determine its potential use as a biomarker for its diagnosis. A prospective cohort study was performed with total 81 participants. These were divided in two groups, i.e., 54 septic patients and 27 healthy volunteers (control group). Among 54 septic participants, half (27) were diabetic, and half (27) were nondiabetic. Blood samples (3 mL) were collected from the control group and the patients who were diagnosed with sepsis and transferred to serum seperator tube. Samples were fractioned and stored at −80 ◦C for further evaluation. These samples were used for the measurement of serum asprosin levels. Demographic characteristics and laboratory data of the patients were recorded in the study form prepared previously. The serum asprosin levels in the control group were 4.1 ± 1.4 ng/mL, 32.8 ± 7 ng/mL in the non-diabetic septic patients and 90.7 ± 5.5 ng/mL in diabetic septic patients. The asprosin level in the non-diabetic group were higher as compared to the control group (p: 0.012), and it was statistically significantly higher in the diabetic group compared to the non-diabetic septic and control groups (both: p < 0.001). Serum asprosin levels were significantly higher in patients with sepsis specially having diabetes. Serum asprosin levels may be beneficial for the diagnosis of sepsis especially in diabetic patients along with the other laboratory parameters white blood cells (WBC), C-reactive protein (CRP), sequential organ failure assessment score (SOFA score) and fewer.


Asprosin; Diabetes mellitus; Diagnosis; Sepsis

Cite and Share

Semra Aytürk Salt,Nurettin Aydoğdu,Ömer Salt,Nihayet Fırat,Necdet Süt. The role of Asprosin in the diagnosis of diabetic and non-diabetic patients with sepsis. Signa Vitae. 2024. 20(5);40-45.


[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315: 801–810.

[2] Vincent J. Current sepsis therapeutics. EBioMedicine. 2022; 86: 104318.

[3] Dellinger RP, Rhodes A, Evans L, Alhazzani W, Beale R, Jaeschke R, et al. Surviving sepsis campaign. Critical Care Medicine. 2023; 51: 431–444.

[4] Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. American Journal of Respiratory and Critical Care Medicine. 2016; 193: 259–272.

[5] Komorowski M, Green A, Tatham KC, Seymour C, Antcliffe D. Sepsis biomarkers and diagnostic tools with a focus on machine learning. EBioMedicine. 2022; 86: 104394.

[6] Feng S, Zhang J. Clinical and microbiological characteristics of type 2 diabetes mellitus accompanied with sepsis. Clinical Laboratory. 2023; 69: 840.

[7] Zonneveld R, Molema G, Plötz FB. Analyzing neutrophil morphology, mechanics, and motility in sepsis. Critical Care Medicine. 2016; 44: 218–228.

[8] Costantini E, Carlin M, Porta M, Brizzi MF. Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence. Acta Diabetologica. 2021; 58: 1139–1151.

[9] Lu Z, Tao G, Sun X, Zhang Y, Jiang M, Liu Y, et al. Association of blood glucose level and glycemic variability with mortality in sepsis patients during ICU hospitalization. Frontiers in Public Health. 2022; 10: 857368.

[10] Donma MM, Donma O. Asprosin: Possible target in connection with ghrelin and cytokine network expression in the post-burn treatment. Medical Hypotheses. 2018; 118: 163–168.

[11] Handa K, Abe S, Suresh VV, Fujieda Y, Ishikawa M, Orimoto A, et al. Fibrillin-1 insufficiency alters periodontal wound healing failure in a mouse model of Marfan syndrome. Archives of Oral Biology. 2018; 90: 53–60.

[12] Sipahioglu H, Sen O, Koyuncu S, Kuzugüden S. Serum asprosin level as a new biomarker in differentiating familial mediterranean fever attacks. Cureus. 2023; 15: e35342.

[13] Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of Inflammation. 2018; 2018: 1–7.

[14] Diao H, Li X, Xu Y, Xing X, Pang S. Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus. Journal of Diabetes and its Complications. 2023; 37: 108614.

[15] Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Military Medical Research. 2022; 9: 56.

[16] Gauer R, Forbes D, Boyer N. Sepsis: diagnosis and management. American Family Physician. 2020; 101: 409–418.

[17] Ma H, Zhang G, Mou C, Fu X, Chen Y. Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Frontiers in Pharmacology. 2018; 9: 156.

[18] Stocker M, van Herk W, el Helou S, Dutta S, Schuerman FABA, van den Tooren-de Groot RK, et al. C-reactive protein, procalcitonin, and white blood count to rule out neonatal early-onset sepsis within 36 hours: a secondary analysis of the neonatal procalcitonin intervention study. Clinical Infectious Diseases. 2021; 73: e383–e390.

[19] Huang Y, Chen C, Shao S, Li C, Hsiao C, Niu K, et al. Comparison of the diagnostic accuracies of monocyte distribution width, procalcitonin, and C-reactive protein for sepsis: a systematic review and meta-analysis. Critical Care Medicine. 2023; 51: e106–e114.

[20] Acara AC, Bolatkale M, Kızıloğlu İ, İbişoğlu E, Can Ç. A novel biochemical marker for predicting the severity of ACS with unstable angına pectoris: asprosin. American Journal of Emergency Medicine. 2018; 36: 1504–1505.

[21] Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel player in metabolic diseases. Frontiers in Endocrinology. 2020; 11: 64.

[22] Lee YS, Olefsky J. Chronic tissue inflammation and metabolic disease. Genes & Development. 2021; 35: 307–328.

[23] Zeng G, Chen D, Zhou R, Zhao X, Ye C, Tao H, et al. Combination of C-reactive protein, procalcitonin, IL-6, IL-8, and IL-10 for early diagnosis of hyperinflammatory state and organ dysfunction in pediatric sepsis. Journal of Clinical Laboratory Analysis. 2022; 36: e24505.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time